Researchers at Pacific Northwest National Laboratory are among those pushing ion mobility spectrometry as a tool to boost complex biological sample analysis.
The company's Q4 revenues were $628.8 million, driven largely by strong pharma and industrial sales; full year 2016 revenues were up 6 percent to $2.17 billion.
The bank rated companies like Thermo Fisher Scientific and Agilent at Buy, Illumina and PerkinElmer at Hold, and Myriad Genetics and Luminex at Sell.
The investment bank said the recent pullback in the company's stock has made its valuation more attractive.
Research centers in six countries will work on metabolome-related global health challenges including autism, cancer, diabetes, dementia, and obesity.
In addition to Illumina and Thermo Fisher, the investment bank reinitiated coverage of Bruker, Invitae, Agilent, Waters, and T2 Biosystems.
Posting strong pharma sales but weakness in academia and government, Waters matched analysts' average EPS estimate for the quarter but fell short on revenues.
Among the launches at the organization's annual meeting this week in Taipei were a personalized proteomics initiative and a new DIA mass spec method.
The company posted Q2 revenues of $536.6 million, up from $494.7 million in Q2 2015 and beating the average Wall Street estimate of $523.4 million.
The mass spectrometry instrument maker will provide A*Star's Bioprocessing Technology Institute with expertise and access to a Synapt G2-S instrument.
CBS This Morning highlights recent Medicare fraud involving offers of genetic testing.
Researchers find that many cancer drugs in development don't work quite how their developers thought they did, as Discover's D-brief blog reports.
Mariya Gabriel, a Bulgarian politician, is to be the next European Union research commissioner, according to Science.
In Science this week: a survey indicates that US adults are more likely to support the agricultural use of gene drives if they target non-native species and if they are limited, and more.